Related Experiment Videos
Immunoadsorption procedure as a potential method for the specific beta 2-microglobulin removal from plasma of
L Vallar1, P M Costa, A Teixeira
1Centre de Recherche INSERM, Vandoeuvre-les-Nancy, France.
Abstract:
beta 2-Microglobulin (beta 2-M), which accumulates in the plasma of patients undergoing long-term dialysis, has been identified as the principal precursor protein of amyloid fibrils in dialysis-related amyloidosis. As no specific treatment for this affection has been yet established, an extracorporeal immunoadsorption procedure appears to be an attractive therapeutic approach to remove beta 2-M. Several murine monoclonal antibodies to human beta 2-M were developed and compared as affinity ligands. One of them was selected on the basis of its specificity and adsorption capacity. In order to achieve maximum efficiency in protein removal, different parameters of the procedure were studied and optimized: effect of antibody coupling density, determination of maximum adsorption capacity of the immunoadsorbents and influence of antigen concentration and of flow-rate on antigen capture efficiency. The conditions of regeneration of immunoaffinity sorbents were also investigated to allow their multiple use without loss of adsorption capacity. The results show the validity of the proposed technique in removing beta-M from plasma of patients with chronic renal failure.
Insights
Dialysis-related amyloidosis involves beta 2-Microglobulin (beta 2-M) buildup. An extracorporeal immunoadsorption technique effectively removes beta 2-M from dialysis patients, offering a promising therapeutic strategy.
Area of Science:
- Nephrology
- Biochemistry
- Immunology
Background:
- Beta 2-Microglobulin (beta 2-M) accumulates in patients on long-term dialysis.
- This accumulation is linked to dialysis-related amyloidosis, where beta 2-M forms amyloid fibrils.
- Currently, no specific treatments exist for this condition.
Purpose of the Study:
- To develop and optimize an extracorporeal immunoadsorption procedure for removing beta 2-M.
- To evaluate monoclonal antibodies as affinity ligands for beta 2-M removal.
- To investigate parameters for efficient and reusable immunoadsorbent systems.
Main Methods:
- Development and comparison of murine monoclonal antibodies against human beta 2-M.
- Optimization of immunoadsorption parameters including antibody coupling density, adsorption capacity, antigen concentration, and flow rate.
- Investigation of immunoadsorbent regeneration conditions for multiple uses.
Main Results:
- A specific monoclonal antibody was selected for its high specificity and adsorption capacity.
- Optimized conditions demonstrated efficient removal of beta 2-M.
- Regeneration protocols allowed for repeated use of immunoadsorbents without significant loss of capacity.
Conclusions:
- Extracorporeal immunoadsorption is a valid and effective technique for removing beta 2-M.
- This method offers a potential therapeutic approach for patients with chronic renal failure and dialysis-related amyloidosis.